CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma

In patients with melanoma, increased RAS/mitogen-activated protein kinase (MAPK) pathway activity is known to drive chemotherapy resistance. Here, the authors identify CDK12 as a downstream effector of the RAS/MAPK pathway and therapeutic target which mediates chemotherapy resistance through increas...

Full description

Bibliographic Details
Main Authors: Thibault Houles, Geneviève Lavoie, Sami Nourreddine, Winnie Cheung, Éric Vaillancourt-Jean, Célia M. Guérin, Mathieu Bouttier, Benoit Grondin, Sichun Lin, Marc K. Saba-El-Leil, Stephane Angers, Sylvain Meloche, Philippe P. Roux
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34179-8

Internet

https://doi.org/10.1038/s41467-022-34179-8

Similar Items